Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - valsartan - film coated tablet - 80 milligram - angiotensin ii antagonists, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - valsartan - film coated tablet - 160 milligram - angiotensin ii antagonists, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - valsartan - film coated tablet - 40 milligram - angiotensin ii antagonists, plain

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - valsartan - film-coated tablet - valsartan 80 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - valsartan - film-coated tablet - valsartan 160 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - valsartan - film-coated tablet - valsartan 320 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - valsartan - film-coated tablet - valsartan 40 mg - agents acting on the renin-angiotensin system

European Union - English - EMA (European Medicines Agency)

hra pharma rare diseases - ketoconazole - cushing syndrome - antimycotics for systemic use - ketoconazole hra is indicated for the treatment of endogenous cushing’s syndrome in adults and adolescents above the age of 12 years.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - valsartan - oral capsule - 80mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - valsartan - oral capsule - 160mg